← FDA DRUG APPROVALS

FDA ANDA · ANDA078737

KETOROLAC TROMETHAMINE

Sponsor: SUN PHARM

APPLICATION
ANDA078737
TYPE
ANDA
ORIGINAL APPROVAL
2008-10-06
LATEST ACTION
2024-11-21
ROUTE
INTRAMUSCULAR, INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

KETOROLAC TROMETHAMINEDiscontinued
KETOROLAC TROMETHAMINE 30MG/ML · INJECTABLE · INJECTION
KETOROLAC TROMETHAMINEDiscontinued
KETOROLAC TROMETHAMINE 15MG/ML · INJECTABLE · INJECTION

Approval history

2024-11-21Labeling · Supplement 20 · standardAP
2023-08-08Labeling · Supplement 16 · standardAP
2023-08-08Labeling · Supplement 19 · standardAP
2021-04-28Labeling · Supplement 15 · standardAP
2019-10-11Labeling · Supplement 3 · standardAP
2016-05-09Labeling · Supplement 4 · standardAP
2008-10-06OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →